SCHEMBL1103027

SCHEMBL1103027

c1ccc(-p2c3ccccc3c3cc(-c4c5ccccc5c(-c5ccc6c(c5)c5ccccc5p6-c5ccccc5)c5ncccc45)ccc32)cc1

nearest known ligand 0.31

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.31
▸ MMP2 P08253 1/20 0.30
▸ CKS1B P61024 1/20 0.30
▸ GLO1 Q04760 1/20 0.30
▸ SKP2 Q13309 1/20 0.30
▸ L3MBTL1 Q9Y468 2/20 0.30
▸ KDM4E B2RXH2 2/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ HSP90AA1 P07900 1/20 0.30
▸ TOP1 P11387 1/20 0.30
▸ KDM6B O15054 1/20 0.30
▸ KDM6A O15550 1/20 0.30
▸ TET3 O43151 1/20 0.30
▸ KDM4A O75164 1/20 0.30
▸ KDM4B O94953 1/20 0.30
▸ KDM5C P41229 1/20 0.30
▸ KDM4D Q6B0I6 1/20 0.30
▸ TET2 Q6N021 1/20 0.30
▸ ALKBH5 Q6P6C2 1/20 0.30
▸ TET1 Q8NFU7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102610 0.81 MAPK10 (0.33) ALDH1A1KDM4ETOP1
SCHEMBL13158630 0.79 ESR1 (0.33) —
SCHEMBL1102946 0.78 ALDH1A1 (0.39) ALDH1A1MMP2L3MBTL1KDM4ENPC1
SCHEMBL1103340 0.77 CDK4 (0.32) —
SCHEMBL13147529 0.77 ALDH1A1 (0.37) ALDH1A1
SCHEMBL1103109 0.76 L3MBTL1 (0.42) ALDH1A1MMP2CKS1BGLO1SKP2
SCHEMBL1103120 0.76 L3MBTL1 (0.42) ALDH1A1MMP2CKS1BGLO1SKP2
SCHEMBL1103081 0.76 L3MBTL1 (0.42) ALDH1A1MMP2CKS1BGLO1SKP2
SCHEMBL1103115 0.76 L3MBTL1 (0.42) ALDH1A1MMP2CKS1BGLO1SKP2
SCHEMBL1102913 0.75 TOP1 (0.38) ALDH1A1MMP2L3MBTL1NPC1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ALDH1A1 1015/4885MMP2 4794/4885CKS1B 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback